What is Ubrelvy (ubrogepant) for?

Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine headaches with or without aura.^[1]

It will not prevent migraine headache.^[1]

It is available in tablet form containing 50 mg or 100 mg ubrogepant.^[1]

How does Ubrelvy (ubrogepant) work?

Ubrogepant is a monoclonal antibody, a type of protein, that blocks the activity of the calcitonin gene-related peptide (CGRP) receptor. CGRP is a molecule that is involved in migraine attacks. When its levels go up, it triggers intense inflammation in the brain, causing migraine headaches.^[2] By blocking the CGRP receptor, ubrogepant can relieve pain experienced during attacks.^[3]

It works without causing constriction in the blood vessels, which some older treatments are known to do.^[4]

Where has Ubrelvy (ubrogepant) been approved?

Ubrelvy (ubrogepant) was approved for the acute treatment of adults with migraine by:

The Food and Drug Administration (FDA), USA, on December 23, 2019.^[4]

It is the first and only CGRP receptor antagonist that can be taken orally for the treatment of migraine attacks.^[4]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Ubrelvy (ubrogepant) taken?

The standard dosage is:^[1]

50 mg or 100 mg taken orally, as needed
A second dose may be administered at least 2 hours after the initial dose for pain relief.

The maximum dose in a 24 hour period is 200 mg.^[1]

Because there is a risk of drug interactions, this medicine should not be used with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin).^[1]

The dose of Ubrelvy (ubrogepant) should be modified when it is used together with specific drugs and for patients with liver (hepatic) or kidney (renal) impairment.^[1]

Complete information about Ubrelvy (ubrogepant) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.